Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash & Current Investments data on file, last reported at $413.0 million in Q1 2026.

• Quarterly Cash & Current Investments fell 16.46% year-over-year to $413.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413.0 million (down 16.46% YoY) and the FY2025 annual result came in at $680.0 million, up 11.48% from the prior year.
• Cash & Current Investments fell to $413.0 million in Q1 2026 per RARE's latest filing, from $680.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $888.7 million in Q3 2022 and bottomed at $412.1 million in Q1 2024.
• The 5-year median for Cash & Current Investments is $577.6 million (2023), against an average of $581.5 million.
• The widest annual swing landed in 2023, when Cash & Current Investments slumped 50.25%; it then soared 40.61% in 2024.
• Tracing RARE's Cash & Current Investments over 5 years: stood at $747.8 million in 2022, then slipped by 22.75% to $577.6 million in 2023, then climbed by 5.6% to $610.0 million in 2024, then climbed by 11.48% to $680.0 million in 2025, then plunged by 39.26% to $413.0 million in 2026.
• Per Business Quant, the three latest RARE Cash & Current Investments figures stand at $413.0 million (Q1 2026), $680.0 million (Q4 2025), and $425.2 million (Q3 2025).

Peer Comparison